tiprankstipranks
Trending News
More News >
CureVac (CVAC)
NASDAQ:CVAC

CureVac (CVAC) AI Stock Analysis

Compare
1,213 Followers

Top Page

CV

CureVac

(NASDAQ:CVAC)

74Outperform
CureVac's overall score reflects a company with substantial financial improvements, attractive valuation, and strategic partnerships, particularly with GSK. The strong cash position and advancements in oncology are positive indicators. However, past volatility in financial performance and operational challenges like restructuring costs remain concerns. The technical indicators suggest moderate positive momentum, enhancing the stock's attractiveness for investors.
Positive Factors
Clinical Trials
CVAC received FDA clearance to initiate the Phase 1 dose-finding trial of CVHNLC in squamous non-small cell lung cancer.
Financial Position
The €400M payment from the amended GSK licensing agreement supports the company's financial position.
Patent Rulings
A positive infringement ruling in Germany would trigger damage assessment proceedings, potentially benefiting Curevac.
Negative Factors
Market Competition
Royalty-bearing flu/COVID programs with GSK are unlikely to drive much value due to their late entries into the market.
Pipeline Development
Pipeline assets from CureVac are still in the very early stages of development and await clinical proof-of-concept before significant value can be assigned.
Restructuring Challenges
The analyst reiterates an underperform rating due to significant derisking needed for pipeline assets amid restructuring and hesitance on the impact of GSK-partnered assets.

CureVac (CVAC) vs. S&P 500 (SPY)

CureVac Business Overview & Revenue Model

Company DescriptionCureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
How the Company Makes MoneyCureVac makes money primarily through the development and commercialization of its mRNA-based therapeutics and vaccines. The company's revenue streams include partnerships and collaborations with other pharmaceutical and biotechnology companies, where they co-develop products and share in the revenue generated from successful products. Additionally, CureVac earns income from licensing agreements, providing access to its proprietary mRNA technology to partners in exchange for upfront payments, milestone payments, and royalties on sales. Significant partnerships with industry leaders and investments in research and development also contribute to CureVac's revenue model, as the company leverages these collaborations to advance its pipeline and bring new products to market.

CureVac Financial Statement Overview

Summary
CureVac demonstrates a significant financial recovery with robust revenue growth and improved profit margins. The balance sheet is strong with low leverage, and cash flow metrics show efficient cash management. However, historical volatility in financial metrics suggests the need for sustained performance.
Income Statement
70
Positive
CureVac's income statement shows a robust turnaround with a significant increase in total revenue in the TTM. The gross profit margin improved to 69.76% from negative values in previous years. The net profit margin also turned positive at 20.36%, reflecting better cost management and operational efficiency. However, historical negative EBIT and EBITDA margins indicate past operational inefficiencies, though current improvements are promising. The revenue growth from the previous year is exceptional at 909.46%, positioning the company well for future growth.
Balance Sheet
65
Positive
The balance sheet reflects a strong equity base with an equity ratio of 84.85% in the TTM, indicating low leverage and financial stability. The debt-to-equity ratio is low at 0.06, suggesting minimal reliance on debt financing. Return on equity has improved significantly to 15.25% in the TTM, indicating efficient use of shareholder funds. However, past fluctuations in equity and liabilities highlight potential volatility.
Cash Flow
75
Positive
CureVac's cash flow statement shows a remarkable recovery with a positive operating cash flow of $128 million in the TTM, compared to significant negative values in prior years. The free cash flow growth is substantial, highlighting better capital expenditure management. The operating cash flow to net income ratio is strong at 1.16, indicating healthy cash generation. The improved free cash flow to net income ratio at 0.90 shows enhanced cash efficiency.
Breakdown
Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
53.76M67.42M102.99M48.90M17.42M
Gross Profit
-70.61M-116.57M-135.21M34.73M-10.57M
EBIT
-274.21M-249.46M-412.26M-124.00M-99.50M
EBITDA
-234.09M-209.39M-386.49M-123.09M-91.50M
Net Income Common Stockholders
-260.17M-249.03M-411.72M-129.07M-99.87M
Balance SheetCash, Cash Equivalents and Short-Term Investments
405.11M500.28M816.11M1.33B32.14M
Total Assets
788.25M860.47M1.16B1.51B130.62M
Total Debt
41.82M42.09M28.89M30.09M79.15M
Net Debt
-360.63M-453.71M-782.57M-1.29B48.46M
Total Liabilities
271.31M327.22M469.77M800.01M173.42M
Stockholders Equity
516.94M533.25M688.48M711.35M-42.80M
Cash FlowFree Cash Flow
-323.09M-379.40M-861.03M475.05M-99.19M
Operating Cash Flow
-267.89M-286.18M-733.13M522.40M-86.96M
Investing Cash Flow
-55.20M-93.50M-127.90M-45.27M28.18M
Financing Cash Flow
230.89M63.17M344.96M819.83M67.98M

CureVac Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.23
Price Trends
50DMA
3.08
Positive
100DMA
3.30
Negative
200DMA
3.20
Positive
Market Momentum
MACD
0.06
Negative
RSI
56.35
Neutral
STOCH
69.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVAC, the sentiment is Positive. The current price of 3.23 is above the 20-day moving average (MA) of 3.00, above the 50-day MA of 3.08, and above the 200-day MA of 3.20, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 56.35 is Neutral, neither overbought nor oversold. The STOCH value of 69.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVAC.

CureVac Risk Analysis

CureVac disclosed 97 risk factors in its most recent earnings report. CureVac reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

CureVac Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$736.26M4.0428.12%910.33%
51
Neutral
$5.31B3.39-40.42%2.90%18.11%2.25%
VIVIR
51
Neutral
$844.95M-38.09%-13.90%16.56%
49
Neutral
$765.83M-14.75%-24.17%-9.24%
47
Neutral
$881.28M-64.16%-30.25%-5.92%
42
Neutral
$725.88M-70.98%249.53%56.59%
40
Underperform
$747.80M-34.74%-36.72%-64.37%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CVAC
CureVac
3.23
0.71
28.17%
XNCR
Xencor
10.51
-10.56
-50.12%
VIR
Vir Biotechnology
6.12
-2.25
-26.88%
NRIX
Nurix Therapeutics
11.56
-0.91
-7.30%
PRAX
Praxis Precision Medicines
36.00
-20.86
-36.69%
ABCL
AbCellera Biologics
2.57
-1.27
-33.07%

CureVac Earnings Call Summary

Earnings Call Date:Apr 10, 2025
(Q4-2024)
|
% Change Since: 8.39%|
Next Earnings Date:May 21, 2025
Earnings Call Sentiment Positive
CureVac has demonstrated strong financial health with a solid cash runway and strategic partnerships, particularly with GSK. Significant progress in oncology and patent validation are positive indicators. However, operational challenges, including a major restructuring and associated costs, pose concerns.
Q4-2024 Updates
Positive Updates
Strong Financial Position
CureVac closed 2024 with a cash position of EUR482 million, providing a solid expected financial runway into 2028.
Strategic Collaboration with GSK
Licensing agreement with GSK valued up to EUR1.45 billion plus royalties, significant upfront payment of EUR400 million received.
Pipeline Advancements in Oncology
Progress in glioblastoma and squamous non-small cell lung cancer programs with anticipated new data and regulatory milestones.
Patent Office Ruling
European Patent Office upheld the validity of CureVac's split poly-A tail 668 patent in amended forms.
Negative Updates
Operational Challenges
Completion of a strategic corporate restructuring involving a headcount reduction of approximately 30%.
Impairment Costs
Impairment of a large-scale production facility, with extraordinary payments amounting to EUR137 million related to past commitments and patent litigation.
Company Guidance
During CureVac's Fourth Quarter and Full Year 2024 financial results and business update call, several key metrics and strategic developments were highlighted. The company ended 2024 with a strong cash position of EUR 482 million, providing a financial runway into 2028. Key achievements included the completion of a strategic restructuring, which involved a 30% reduction in workforce, anticipated to decrease operating expenses by over 30% and reduce personnel costs by EUR 25 million. CureVac's collaboration with GSK, valued at up to EUR 1.45 billion plus royalties, generated a EUR 400 million upfront payment and a EUR 10 million milestone payment in the fourth quarter. In oncology, CureVac's Phase 1 glioblastoma study demonstrated promising results, and the company plans to advance to Phase 2 pending further data in the second half of 2025. In infectious diseases, a licensing agreement with GSK continues to progress, with a combined Phase 1/2 study for a seasonal influenza and COVID combination vaccine underway. The company also emphasized progress in its IP litigation, with the European Patent Office upholding the validity of a critical patent, reinforcing CureVac's leadership in mRNA technology.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.